132748-20-0|JG 365|methyl (3-((S)-2-((S)-2-((S)-2-acetamido-3-hydroxypropanamido)-4-methylpentanamido)-4-amino-4-oxobutanamido)-2-hydroxy-4-phenylbutyl)-L-prolyl-L-isoleucyl-L-valinate|-范德生物科技公司

JG 365

NMR下载 COA and HPLC MSDS下载
names：
methyl (3-((S)-2-((S)-2-((S)-2-acetamido-3-hydroxypropanamido)-4-methylpentanamido)-4-amino-4-oxobutanamido)-2-hydroxy-4-phenylbutyl)-L-prolyl-L-isoleucyl-L-valinate
CAS号：
132748-20-0
MDL Number：
MF(分子式)： C42H68N8O11 MW(分子量)： 861.05
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)
FMK16594-100mg	100mg	>98%	¥ 0.00	¥ 0.00		Get quote	- +	¥ 0.00

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	JG 365
英文别名	JG 365; JG-365; JG365;
CAS号	132748-20-0
Inchi	InChI=1S/C42H68N8O11/c1-9-25(6)36(41(59)48-35(24(4)5)42(60)61-8)49-40(58)32-16-13-17-50(32)21-33(53)28(19-27-14-11-10-12-15-27)45-38(56)30(20-34(43)54)47-37(55)29(18-23(2)3)46-39(57)31(22-51)44-26(7)52/h10-12,14-15,23-25,28-33,35-36,51,53H,9,13,16-22H2,1-8H3,(H2,43,54)(H,44,52)(H,45,56)(H,46,57)(H,47,55)(H,48,59)(H,49,58)/t25-,28?,29-,30-,31-,32-,33?,35-,36-/m0/s1
InchiKey	MJOXWVYKMFPFPL-AIVXTZMUSA-N
分子式 Formula	C42H68N8O11
分子量 Molecular Weight	861.05
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	JG 365(CAS:132748-20-0):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	JG 365 is a HIV protease inhibitor.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Johnson EC, Malito E, Shen Y, Pentelute B, Rich D, Florián J, Tang WJ, Kent SB. Insights from atomic-resolution X-ray structures of chemically synthesized HIV-1 protease in complex with inhibitors. J Mol Biol. 2007 Oct 26;373(3):573-86. Epub 2007 Aug 2. PubMed PMID: 17869270; PubMed Central PMCID: PMC2094697.

[2]Cieplak P. Some computational aspects of theoretical anti-HIV drug design. Acta Pol Pharm. 2000 Nov;57 Suppl:33-6. PubMed PMID: 11293258.

[3] Popov ME, Kashparov IV, Rumsh LD, Popov EM. [Mechanism of aspartyl proteinase action. VII. Noncovalent complexes of HIV-1 aspartyl proteinase with substrate and substrate-like inhibitors]. Bioorg Khim. 1999 Dec;25(12):911-22. Russian. PubMed PMID: 10734551.

[4] Popov ME, Kashparov IV, Rumsh LD, Popov EM. [Mechanism of action of aspartic proteases. III. Conformational characteristics of HIV-1 protease inhibitor JG-365]. Bioorg Khim. 1999 Jun;25(6):418-22. Russian. PubMed PMID: 10505229.

[5] Martin JL, Begun J, Schindeler A, Wickramasinghe WA, Alewood D, Alewood PF, Bergman DA, Brinkworth RI, Abbenante G, March DR, Reid RC, Fairlie DP. Molecular recognition of macrocyclic peptidomimetic inhibitors by HIV-1 protease. Biochemistry. 1999 Jun 22;38(25):7978-88. PubMed PMID: 10387041.

6: Ding YS, Rich DH, Ikeda RA. Substrates and inhibitors of human T-cell leukemia virus type I protease. Biochemistry. 1998 Dec 15;37(50):17514-8. PubMed PMID: 9860866.7: Lee CY, Yang PK, Tzou WS, Hwang MJ. Estimates of relative binding free energies for HIV protease inhibitors using different levels of approximations. Protein Eng. 1998 Jun;11(6):429-37. PubMed PMID: 9725621.8: Mestres J, Rohrer DC, Maggiora GM. A molecular field-based similarity approach to pharmacophoric pattern recognition. J Mol Graph Model. 1997 Apr;15(2):114-21, 103-6. PubMed PMID: 9385558.9: Laskowski RA, Thornton JM, Humblet C, Singh J. X-SITE: use of empirically derived atomic packing preferences to identify favourable interaction regions in the binding sites of proteins. J Mol Biol. 1996 May 31;259(1):175-201. PubMed PMID: 8648645.10: Verkhivker GM. Empirical free energy calculations of human immunodeficiency virus type 1 protease crystallographic complexes. II. Knowledge-based ligand-protein interaction potentials applied to thermodynamic analysis of hydrophobic mutations. Pac Symp Biocomput. 199

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开